Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9604656 | 0.86 | NUAK1 (0.34) | CAPN1NUAK1IGF1RMETPIM1 | |
| SCHEMBL9604655 | 0.77 | NUAK1 (0.34) | CAPN1NUAK1IGF1RMETPIM1 | |
| SCHEMBL9606821 | 0.74 | NUAK1 (0.35) | NUAK1IGF1RMETPIM1SRC | |
| SCHEMBL9604658 | 0.70 | NUAK1 (0.38) | NUAK1IGF1RMETPIM1SRC | |
| SCHEMBL20930868 | 0.67 | KCNJ1 (0.38) | NUAK1IGF1RMETPIM1SRC | |
| SCHEMBL9604657 | 0.66 | NUAK1 (0.38) | NUAK1IGF1RMETPIM1SRC | |
| SCHEMBL20930883 | 0.66 | TSHR (0.47) | CAPN1TSHR | |
| SCHEMBL12847433 | 0.64 | TSHR (0.44) | CAPN1TSHR | |
| SCHEMBL25463387 | 0.63 | TSHR (0.38) | TSHR | |
| SCHEMBL18595099 | 0.63 | TSHR (0.38) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | CAPN1 261/4885NUAK1 2421/4885IGF1R 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.